Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 11/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532115 | 0.83 | KDM1A (0.60) | MMP2MMP13EDNRAKDM1ANPC1 | |
| SCHEMBL27593866 | 0.82 | EDNRA (0.62) | MMP2MMP13EDNRANPC1RAB9A | |
| SCHEMBL23532178 | 0.81 | KDM1A (0.52) | EDNRAKDM1ANPC1RAB9AMAPT | |
| SCHEMBL20305366 | 0.79 | EDNRA (0.71) | MMP2MMP13EDNRANPC1RAB9A | |
| SCHEMBL3609409 | 0.76 | RAB9A (0.72) | NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4109825 | 0.76 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2TP53TSHR | |
| SCHEMBL3618186 | 0.74 | EDNRA (0.56) | EDNRAKDM1ANPC1RAB9AMAPT | |
| SCHEMBL28381838 | 0.72 | MAPT (0.62) | MMP2MMP13EDNRAKDM1ANPC1 | |
| SCHEMBL21665556 | 0.70 | CYP3A4 (0.48) | MMP2MMP13EDNRASMN1; SMN2TSHR | |
| SCHEMBL2299529 | 0.69 | PLK1 (0.50) | MMP2NPC1RAB9AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | MMP2 2588/4885MMP13 3189/4885EDNRA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.